Contact Us (781) 301-7474

Hemanext is a privately held medical technology company dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy. The company’s research and development efforts center on the study of hypoxically stored red blood cells (RBCs).

Corporate Hemanext Video

Educational Symposiums

Patient Advocacy Groups

Supporting the AABB Community:

Hemanext

AABB Corporate Partner Spotlight

For more than a decade, Hemanext has committed its resources to the transfusion medicine community through its investments and its research — research that has garnered several National Institutes of Health grants worth $8.2 million and AABB’s RISE Award in 2021.

READ MORE >>

AABB’S CORPORATE PARTNER PROGRAM focuses on celebrating the vital work of corporate members of the blood and biotherapies community.